Literature DB >> 9502784

Various mechanisms cause RET-mediated signaling defects in Hirschsprung's disease.

A Pelet1, O Geneste, P Edery, A Pasini, S Chappuis, T Atti, A Munnich, G Lenoir, S Lyonnet, M Billaud.   

Abstract

Hirschsprung's disease (HSCR) is a common congenital malformation characterized by the absence of intramural ganglion cells of the hindgut. Recently, mutations of the RET tyrosine kinase receptor have been identified in 50 and 15-20% of familial and sporadic HSCR, respectively. These mutations include deletion, insertion, frameshift, nonsense, and missense mutations dispersed throughout the RET coding sequence. To investigate their effects on RET function, seven HSCR missense mutations were introduced into either a 1114-amino acid wild-type RET isoform (RET51) or a constitutively activated form of RET51 (RET-MEN 2A). Here, we report that one mutation affecting the extracytoplasmic cadherin domain (R231H) and two mutations located in the tyrosine kinase domain (K907E, E921K) impaired the biological activity of RET-MEN 2A when tested in Rat1 fibroblasts and pheochromocytoma PC12 cells. However, the mechanisms resulting in RET inactivation differed since the receptor bearing R231H extracellular mutation resulted in an absent RET protein at the cell surface while the E921K mutation located within the catalytic domain abolished its enzymatic activity. In contrast, three mutations mapping into the intracytoplasmic domain neither modified the transforming capacity of RET-MEN 2A nor stimulated the catalytic activity of RET in our ligand-independent system (S767R, P1039L, M1064T). Finally, the C609W HSCR mutation exerts a dual effect on RET since it leads to a decrease of the receptor at the cell surface and converted RET51 into a constitutively activated kinase due to the formation of disulfide-linked homodimers. Taken together, our data show that allelic heterogeneity at the RET locus in HSCR is associated with various molecular mechanisms responsible for RET dysfunction.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9502784      PMCID: PMC508697          DOI: 10.1172/JCI375

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  47 in total

1.  RET alternate splicing influences the interaction of activated RET with the SH2 and PTB domains of Shc, and the SH2 domain of Grb2.

Authors:  M J Lorenzo; G D Gish; C Houghton; T J Stonehouse; T Pawson; B A Ponder; D P Smith
Journal:  Oncogene       Date:  1997-02-20       Impact factor: 9.867

2.  The ret oncogene products are membrane-bound glycoproteins phosphorylated on tyrosine residues in vivo.

Authors:  M Taniguchi; T Iwamoto; M Hamaguchi; M Matsuyama; M Takahashi
Journal:  Biochem Biophys Res Commun       Date:  1991-11-27       Impact factor: 3.575

3.  Production of high-titer helper-free retroviruses by transient transfection.

Authors:  W S Pear; G P Nolan; M L Scott; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

4.  Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line.

Authors:  J P Morgenstern; H Land
Journal:  Nucleic Acids Res       Date:  1990-06-25       Impact factor: 16.971

5.  Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains.

Authors:  M Takahashi; Y Buma; T Iwamoto; Y Inaguma; H Ikeda; H Hiai
Journal:  Oncogene       Date:  1988-11       Impact factor: 9.867

Review 6.  The protein kinase family: conserved features and deduced phylogeny of the catalytic domains.

Authors:  S K Hanks; A M Quinn; T Hunter
Journal:  Science       Date:  1988-07-01       Impact factor: 47.728

7.  A gene for Hirschsprung disease (megacolon) in the pericentromeric region of human chromosome 10.

Authors:  M Angrist; E Kauffman; S A Slaugenhaupt; T C Matise; E G Puffenberger; S S Washington; A Lipson; D T Cass; T Reyna; D E Weeks
Journal:  Nat Genet       Date:  1993-08       Impact factor: 38.330

8.  A branched signaling pathway for nerve growth factor is revealed by Src-, Ras-, and Raf-mediated gene inductions.

Authors:  G D'Arcangelo; S Halegoua
Journal:  Mol Cell Biol       Date:  1993-06       Impact factor: 4.272

9.  A gene for Hirschsprung disease maps to the proximal long arm of chromosome 10.

Authors:  S Lyonnet; A Bolino; A Pelet; L Abel; C Nihoul-Fékété; M L Briard; V Mok-Siu; H Kaariainen; G Martucciello; M Lerone; A Puliti; Y Luo; J Weissenbach; M Devoto; A Munnich; G Romeo
Journal:  Nat Genet       Date:  1993-08       Impact factor: 38.330

10.  Characterization of the ret proto-oncogene products expressed in mouse L cells.

Authors:  M Takahashi; N Asai; T Iwashita; T Isomura; K Miyazaki; M Matsuyama
Journal:  Oncogene       Date:  1993-11       Impact factor: 9.867

View more
  28 in total

1.  A human model for multigenic inheritance: phenotypic expression in Hirschsprung disease requires both the RET gene and a new 9q31 locus.

Authors:  S Bolk; A Pelet; R M Hofstra; M Angrist; R Salomon; D Croaker; C H Buys; S Lyonnet; A Chakravarti
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

Review 2.  Hirschsprung disease, associated syndromes, and genetics: a review.

Authors:  J Amiel; S Lyonnet
Journal:  J Med Genet       Date:  2001-11       Impact factor: 6.318

3.  A founding locus within the RET proto-oncogene may account for a large proportion of apparently sporadic Hirschsprung disease and a subset of cases of sporadic medullary thyroid carcinoma.

Authors:  Salud Borrego; Fred A Wright; Raquel M Fernández; Nita Williams; Manuel López-Alonso; Ramana Davuluri; Guillermo Antiñolo; Charis Eng
Journal:  Am J Hum Genet       Date:  2002-12-09       Impact factor: 11.025

Review 4.  Dependence receptors: between life and death.

Authors:  P Mehlen; C Thibert
Journal:  Cell Mol Life Sci       Date:  2004-08       Impact factor: 9.261

Review 5.  [Molecular biology, basic research and diagnosis of Hirschsprung's disease].

Authors:  G Martucciello; O Luinetti; P Romano; U Magrini
Journal:  Pathologe       Date:  2007-03       Impact factor: 1.011

Review 6.  Genetic basis of Hirschsprung's disease.

Authors:  Paul K H Tam; Mercè Garcia-Barceló
Journal:  Pediatr Surg Int       Date:  2009-06-12       Impact factor: 1.827

7.  Hirschsprung disease of the colon, a vaginal mass and medullary thyroid cancer - a RET oncogene driven problem.

Authors:  Romy Pandey; Tiffany Thurow; Robert de W Marsh
Journal:  J Gastrointest Oncol       Date:  2011-12

Review 8.  The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer.

Authors:  Valentina De Falco; Francesca Carlomagno; Hong-Yu Li; Massimo Santoro
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2017-05-10       Impact factor: 4.690

9.  The risk of medullary thyroid carcinoma in patients with Hirschsprung's disease.

Authors:  Richard Skába; Sárka Dvoráková; Eliska Václavíková; Petr Vlcek; Miroslava Frantlová; Bela Bendlová
Journal:  Pediatr Surg Int       Date:  2006-12       Impact factor: 1.827

Review 10.  Structure and physiology of the RET receptor tyrosine kinase.

Authors:  Carlos F Ibáñez
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-02-01       Impact factor: 10.005

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.